CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 1,087 enrolled
Drug / intervention
Prevenar (13v)drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02119104
NCT02119104N/ACompleted
CompareCT.gov

Prevenar (13v) Infant Drug Use Investigation (Regulatory Post Marketing Commitment Plan)

Pfizer·observational·Posted Apr 21, 2014·Updated Jun 19, 2017

In Brief

An observational study evaluating Prevenar (13v) for Infants. Completed, enrolled 1,087 participants.

Detailed Summary

The purpose of this study is to investigate post marketing use and safety of Prevnar ( 13v) in infants vaccinated for the first time at the age of 2 months, inclusive, to 7 months, exclusive.

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsInfants
Countries--
Collaborators--

Timeline

N/ACompletedFinished
2014201520162017201820192020202120222023202420252026
First PostedApr 21, 2014
Enrollment StartMar 1, 2014
Primary CompletionMay 1, 2016
TodayJul 2, 2026
Enrollment to primary: 2.2 yearsPosted 12.2 years ago

Interventions

Prevenar (13v)drug

Prevenar (13v)